All In Biotech

Drug Trial Radar · NCT03035305

Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali

Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Kolokani Circle, Koulikoro Region, Mali, August-November 2016: Interventional Matched-pair Clustered Cohort

Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36,717

Actual

Start

Aug 2016

Primary completion

Nov 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Alliance for International Medical ActionAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France; Alliance médicale contre le paludisme, Mali; Programme National de Lutte contre le Paludisme, Niger; United States Agency for International Development (USAID); European Commission; Ministry of health, Mali
First posted
Jan 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SMC LNS Mali is a interventional matched-pair clustered cohort carried out between August and November 2017 in 18 health areas in Kolokani Circle, Koulikoro region, Mali. The objective of this study is to determine whether the association SMC and LNS reduces the number of confirmed malaria cases among children 6-59 months during the monthly SMC distribution sessions.

Conditions

  • Malaria

Interventions

  • Lipid-based Nutrient Supplement (LNS)Dietary supplement

    For each round of SMC distribution (total of 4 rounds): * For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks * For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks

  • Seasonal malaria chemopreventionDrug

    For each round of SMC distribution (total of 4 rounds): * For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg * For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed malaria caseTime frame: From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amcp/Alima

    Kolokani Circle, Koulikoro, Mali

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.